Nippon Boehringer Ingelheim Co., Ltd
Tokyo, 1416017, Japan
NCT Number: NCT03761797
Study objectives is to investigate the safety of long-term daily use of TRADIANCE® Combination Tablets AP and BP in Japanese patients with Type 2 Diabetes mellitus (T2DM) used in routine care.
Looking for future studies?
Notify MeAll sexes
Observational
Tokyo, 1416017, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
None
Fixed dose combination
Fixed dose combination
Time frame: From first dose of study medication until last dose + 7 days, up to 102.1 weeks.
The number of participants with adverse drug reactions is reported.
Boehringer Ingelheim
Industry
Post Marketing Surveillance in Japan on Long Term Drug Use of TRADIANCE® Combination Tablets AP and BP in Patients With Type 2 Diabetes Mellitus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00340132
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT01878045
Diabetes Complications, Diabetes Mellitus
Phoenix, Arizona, United States
View Trial DetailsNCT04504968
Diabetes Mellitus, Diabetes Mellitus, Type 2
Bogotá, Colombia
View Trial DetailsNCT00339482
Cardiovascular Diseases, Diabetes Mellitus
Phoenix, Arizona, United States
View Trial Details